Copyright
©The Author(s) 2022.
World J Gastroenterol. Jul 28, 2022; 28(28): 3595-3607
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3595
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3595
Ref. | Interventions | Mechanisms of action | Main results |
Llovet et al[57] | Sorafenib × placebo | TKI × placebo | Increased OS with sorafenib |
Cheng et al[56] | Sorafenib × placebo | TKI × placebo | Increased OS with sorafenib |
Bruix1 et al[59] | Regorafenib × placebo | TKI × placebo | Increased OS with regorafenib |
Kudo et al[61] | Lenvatinib × sorafenib | TKI × TKI | Non-inferior OS |
Abou-Alfa2 et al[58] | Cabozantinib × placebo | TKI × placebo | Increased OS with cabozantinib |
Zhu1,3 et al[60] | Ramucirumab × placebo | Anti-VEGF receptor 2 × placebo | Increased OS with ramucirumab |
Yau et al[73] | Nivolumab × sorafenib | Anti-PD-1 × TKI | No increase in OS4 |
Finn1 et al[74] | Pembrolizumab × placebo | Anti-PD-L1 × placebo | No increase in OS4 |
Finn et al[19] | Atezolizumab + bevacizumab × sorafenib | Anti-PD-L1 + anti-VEGF × TKI | Increased OS with atezolizumab + bevacizumab |
Kelley et al[79] | Atezolizumab + cabozantinib × sorafenib × cabozantinib | Anti-PD-L1 + TKI × TKI × TKI | No increase in OS4 |
Abou-Alfa et al[82] | Tremelimumab + durvalumab × durvalumab × sorafenib | Anti-CTLA-4 + anti-PD-L1 × anti-PD-L1 × TKI | Increased OS with tremelimumab + durvalumab (× sorafenib). Non-inferior OS with durvalumab (× sorafenib) |
- Citation: Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607
- URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3595.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i28.3595